Zacks Investment Research·2d ago
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayFour biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Prothena's financial profile is defined by extreme revenue lumpiness, with quarterly swings from $51.1M in 2026Q1 to $1.0M in 2026Q2, suggesting a model reliant on non-recurring licensing milestones rather than sustainable product sales. The company's cost str...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.32+17.9% vs -$0.39 | $1M+139.5% vs $421,667 |
Q2 2026 May 7, 2026 | $0.60+293.5% vs -$0.31 | $51M+6215.2% vs $808,909 |
Q1 2026 Feb 19, 2026 | -$0.44+2.2% vs -$0.45 | $21,000-98.4% vs $1M |
Q4 2025 Nov 6, 2025 | -$0.67-11.7% vs -$0.60 | $2M+262.2% vs $666,670 |
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
Benchmark PRTA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Prothena Corporation plc (PRTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.68 | $454.43M | -1.92 | -92.84% | -2520.57% | -63.62% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — |
Prothena Corporation plc (PRTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Prothena Corporation plc (PRTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 15, 2026·SEC
May 7, 2026·SEC
Get notified when PRTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Prothena Corporation plc (PRTA) stock FAQ — growth, dividends, profitability & financials explained
Prothena Corporation plc (PRTA) reported $54.5M in revenue for fiscal year 2025. This represents a 4287% increase from $1.2M in 2010.
Prothena Corporation plc (PRTA) saw revenue decline by 92.8% over the past year.
Prothena Corporation plc (PRTA) reported a net loss of $44.0M for fiscal year 2025.
Prothena Corporation plc (PRTA) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
Prothena Corporation plc (PRTA) had negative free cash flow of $60.7M in fiscal year 2025, likely due to heavy capital investments.
